BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Maraone A, Tarsitani L, Pinucci I, Pasquini M. Antiglutamatergic agents for obsessive-compulsive disorder: Where are we now and what are possible future prospects? World J Psychiatr 2021; 11(9): 568-580 [PMID: 34631461 DOI: 10.5498/wjp.v11.i9.568]
URL: https://www.wjgnet.com/2220-3206/full/v11/i9/568.htm
Number Citing Articles
1
Rakesh Sahu. Exploring Biomarkers and Contributing Factors in Obsessive-Compulsive Disorder: HypothesisAcademic Bulletin of Mental Health 2024; 2: 54 doi: 10.25259/ABMH_12_2024
2
Annalisa Maraone, Alessandro Trebbastoni, Antonella Di Vita, Fabrizia D'Antonio, Carlo De Lena, Massimo Pasquini. Memantine for Refractory Obsessive-Compulsive Disorder: Protocol for a Pragmatic, Double-blind, Randomized, Parallel-Group, Placebo-Controlled, Monocenter TrialJMIR Research Protocols 2023; 12: e39223 doi: 10.2196/39223
3
Júlia Grigorini Mori Ayub, Cristina Luz Tosta, Breno Lopes Macedo, Tattyanna Fernandes Barreto, Lorena Martins Lopes, Maria Paula dos Santos Fracalossi, Roberto Andreatini, Vanessa Beijamini. S-ketamine exerts sex- and dose-dependent anti-compulsive-like effect as monotherapy or in augmentation to fluoxetineEuropean Journal of Pharmacology 2022; 937: 175382 doi: 10.1016/j.ejphar.2022.175382
4
Sydney Raboin. Visualizing victory: the role of imagery in empowering athletes battling obsessive-compulsive disorderJournal of Imagery Research in Sport and Physical Activity 2024; 19(s1) doi: 10.1515/jirspa-2024-0006
5
Rituparna Maiti, Archana Mishra, Anand Srinivasan, Biswa Ranjan Mishra. Pharmacological augmentation of serotonin reuptake inhibitors in patients with obsessive–compulsive disorder: A network meta‐analysisActa Psychiatrica Scandinavica 2023; 148(1): 19 doi: 10.1111/acps.13568